Novel AI-Driven Model Validated to Predict Risk of Chronic Kidney Disease Progression in Large U.S. Study

Boehringer Ingelheim and Carelon Research have conducted the first large-scale U.S. validation of a new AI-driven tool for chronic kidney disease (CKD) The Klinrisk model predicted disease progression in over 80% of individuals at all stages of the disease, based on data from a diverse population of over 4 million U.S. adults Validated tools to […]

Related Keywords

Ridgefield ,Pennsylvania ,United States ,Germany ,Ingelheim ,Rheinland Pfalz ,Philadelphia ,American ,Navdeep Tangri ,Mohamed Eid ,Mark Cziraky ,Carelon Research ,Boehringer Ingelheim Pharmaceuticals Inc ,American Society Of Nephrology ,Clinical Development Medical Affairs ,Boehringer Ingelheim ,Elevance Health ,Animal Health ,American Society ,Kidney Week ,Clinical Development ,Medical Affairs ,Respiratory Medicine ,Boehringer Ingelheim Pharmaceuticals ,Human Pharma ,Corporate Headquarters ,Ingelheim Pharmaceuticals ,